Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
23.6M
-
Number of holders
-
35
-
Total 13F shares, excl. options
-
6.66M
-
Shares change
-
+640K
-
Total reported value, excl. options
-
$9.54M
-
Value change
-
+$864K
-
Number of buys
-
14
-
Number of sells
-
-12
-
Price
-
$1.40
Significant Holders of Rein Therapeutics, Inc. - Common Stock, $0.001 par value (RNTX) as of Q2 2025
42 filings reported holding RNTX - Rein Therapeutics, Inc. - Common Stock, $0.001 par value as of Q2 2025.
Rein Therapeutics, Inc. - Common Stock, $0.001 par value (RNTX) has 35 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.66M shares
of 23.6M outstanding shares and own 28.21% of the company stock.
Largest 10 shareholders include BIOS Capital Management, LP (1.69M shares), Voss Capital, LP (1.43M shares), VANGUARD GROUP INC (884K shares), UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO (512K shares), Prosight Management, LP (428K shares), Cable Car Capital, LP (420K shares), Sigma Planning Corp (277K shares), GEODE CAPITAL MANAGEMENT, LLC (245K shares), Senvest Management, LLC (231K shares), and GAGNON SECURITIES LLC (71.7K shares).
This table shows the top 35 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.